Appellate Authority Confirms ₹155 Crore Tax Demand on Aurobindo Pharma — GST Demand + Equal Penalty Upheld

Aurobindo Pharma Limited (NSE: AUROPHARMA) — one of India's largest pharmaceutical manufacturers and a top-10 global generics player — has received a significant regulatory setback. The Principal Commissioner of Customs and Central Tax (Appeals I), Hyderabad, has confirmed a GST demand of ₹77,61,35,242 along with an equal penalty amount — bringing the total confirmed liability to approximately ₹155 crore. The pharmaceutical company received the appellate order on March 12, 2026, and informed stock exchanges on March 13, 2026, in compliance with SEBI Regulation 30. Here is a complete breakdown of the case, the three allegations, what has been paid, and what comes next.

The Three Allegations: What the GST Authorities Found

The confirmed demand stems from three primary allegations against the company during the period from July 1, 2017, to March 23, 2020:

  • Allegation 1 — Excess IGST Refunds (CIF vs FOB Valuation): Tax authorities alleged that Aurobindo Pharma availed excess IGST refunds based on CIF (Cost, Insurance and Freight) versus FOB (Free on Board) valuations. Under Indian GST law, export refunds are calculated on FOB value — the value of goods at the port of shipment, excluding insurance and freight. If Aurobindo included CIF components in its refund base, the excess refund claimed would be recoverable with interest and penalty.
  • Allegation 2 — Non-Surrender of IGST Refunds on Short Realisation: Aurobindo failed to surrender IGST refunds on account of short realisation of export proceeds under Rule 96 of CGST Rules. Where export proceeds are not fully realised from overseas buyers within the prescribed RBI timeframe, IGST refunds already received must be proportionally reversed — a compliance requirement Aurobindo allegedly did not fully honour.
  • Allegation 3 — Non-Reversal of ITC under Rule 37: Aurobindo did not reverse Input Tax Credit as required under Rule 37 of CGST Rules. Rule 37 mandates ITC reversal where payment to suppliers is not made within 180 days — a GST cashflow compliance rule that Aurobindo allegedly failed to follow for a portion of its input purchases during the audit period.

The case covers a three-year audit window — the critical initial years of GST implementation in India (2017–2020) — when system-level mismatches, rule interpretations, and compliance gaps were pervasive across the pharmaceutical industry. For the definitive statutory framework governing IGST refunds, ITC reversal, and export compliance, the Central Board of Indirect Taxes and Customs (CBIC) official CGST Act and Rules is the authoritative primary reference for all legal and compliance purposes.

What the Appellate Authority Upheld — and What It Dropped

The appellate outcome was not a complete defeat for Aurobindo — the order was a partial allowance of the company's appeal:

The Principal Commissioner of Customs and Central Tax (Appeals I), Hyderabad, partially allowed the company's appeal by dropping the demand for interest on ITC reversed under Rule 37 of CGST Rules — but upheld the original GST demand of ₹77.61 crore and the equal penalty of ₹77.61 crore in all other respects.

The dropping of interest on the Rule 37 ITC reversal is a meaningful but limited concession — it removes one layer of carrying cost from the liability but leaves the principal demand and the penalty fully intact. The confirmed total liability of approximately ₹155 crore (₹77.61 crore tax + ₹77.61 crore penalty) remains the number that Aurobindo must now challenge before the GST Appellate Tribunal (GSTAT).

What Aurobindo Has Already Paid: Proactive Compliance Under Protest

Aurobindo Pharma has not been passive in the face of this escalating GST dispute — it has taken proactive compliance steps that are now formally acknowledged by the tax authority:

Aurobindo Pharma has already taken proactive measures by paying ₹23,71,71,782 under protest and reversing ITC of ₹8,78,23,385 — both of which have been accepted by the tax authorities.

The "payment under protest" mechanism is significant in Indian tax jurisprudence — it demonstrates compliance intent, stops interest from accruing on the paid portion, and typically reduces the practical dispute at GSTAT to the remaining unpaid quantum of approximately ₹53.9 crore of the principal demand plus the full ₹77.61 crore penalty. The ITC reversal of ₹8.78 crore being accepted by the department further narrows the practical quantum under dispute.

Next Step: GSTAT Appeal Within Stipulated Timeframe

Aurobindo Pharma has indicated its intention to file an appeal against the appellate order dated February 27, 2026, before the Goods and Services Tax Appellate Tribunal (GSTAT) within the stipulated timeframe. This represents the next level of judicial review available to challenge the confirmed GST demand and penalty.

GSTAT — India's specialised appellate body for GST disputes — is the third tier in the GST dispute resolution hierarchy, after the original adjudicating authority and the Commissioner (Appeals). GSTAT proceedings typically take 18–36 months to conclude for complex matters of this size. The tribunal has the power to set aside, reduce, or modify the demand and penalty — and its rulings on FOB vs CIF valuation methodology for IGST refunds will have significant precedential value for the broader pharmaceutical and export manufacturing sector.

The Broader GST Dispute Picture: ₹155 Crore Is Not Aurobindo's Only Open Case

This is not the first — and almost certainly not the last — GST demand disclosure from Aurobindo Pharma in recent months. The company disclosed a separate ₹169.83 crore GST demand on February 18, 2026 — issued by the Additional Commissioner of Central Tax, Ranga Reddy GST Commissionerate — related to alleged erroneous refunds of accumulated ITC under Rule 89 of CGST Rules for the period September 2022 to December 2022 through its EOU Unit 3. Against this earlier demand, Aurobindo has filed writ petitions before the Telangana High Court, where the matter is currently pending.

The cumulative picture of Aurobindo's open GST litigation — covering multiple audit periods, multiple GST commissionerates in Hyderabad, and multiple legal mechanisms from Commissioner Appeals to High Court writ petitions — reflects a broader industry-wide phenomenon. India's GST implementation in 2017 created structural compliance gaps for large exporters and EOU units that the department is systematically now auditing and recovering, several years after the fact.

Stock and Financial Impact: "No Material Impact" — Company's Official Position

Aurobindo Pharma has stated that there is no material impact on the company's financials or operations due to the confirmed order. This standard SEBI disclosure language is technically supportable: Aurobindo's Q3 FY26 revenue from operations was approximately ₹8,200 crore, with net profit of approximately ₹900–950 crore. A ₹155 crore contingent liability — of which ₹23.71 crore is already paid under protest — represents less than 2% of quarterly revenue and approximately 16% of a single quarter's net profit.

However, the directional signal — a confirmed appellate loss on an amount of this scale, adding to the ₹169.83 crore demand already in litigation — suggests that Aurobindo's total open GST contingency exposure across all pending cases may be material in aggregate, even if each individual case is characterised as non-material.

Key Facts at a Glance

  • Company: Aurobindo Pharma Limited (NSE: AUROPHARMA / BSE: 524804)
  • Appellate Authority: Principal Commissioner of Customs and Central Tax (Appeals I), Hyderabad
  • Order Date: February 27, 2026
  • Order Received: March 12, 2026
  • Stock Exchange Disclosure: March 13, 2026 (SEBI Regulation 30 compliant)
  • GST Demand Confirmed: ₹77,61,35,242 (~₹77.61 crore)
  • Equal Penalty Confirmed: ₹77,61,35,242 (~₹77.61 crore)
  • Total Confirmed Liability: ~₹155.22 crore
  • Audit Period: July 1, 2017 – March 23, 2020
  • Allegation 1: Excess IGST refunds — CIF vs FOB valuation
  • Allegation 2: Non-surrender of IGST refunds on short export realisation (Rule 96, CGST)
  • Allegation 3: Non-reversal of ITC within 180 days (Rule 37, CGST)
  • Partial Relief Granted: Interest on Rule 37 ITC reversal dropped
  • Amount Paid Under Protest: ₹23,71,71,782
  • ITC Reversed (Accepted by Dept): ₹8,78,23,385
  • Next Step: GSTAT appeal (Goods and Services Tax Appellate Tribunal)
  • Financial Impact (Company View): No material impact on financials or operations
  • Separate Pending GST Case: ₹169.83 crore (Ranga Reddy Commissionerate — Telangana HC writ pending)
  • Company Secretary: B. Adi Reddy

Conclusion

The appellate authority's confirmation of a ₹155 crore GST demand and penalty on Aurobindo Pharma is a significant regulatory development — but not an unexpected one in the context of India's systematic post-GST audit programme targeting exporters and EOU units from the 2017–2020 initial implementation years. The partial relief — dropping of interest on Rule 37 ITC — is meaningful but does not materially alter the exposure quantum.

With ₹23.71 crore already paid under protest, ₹8.78 crore of ITC reversed and accepted, and a GSTAT appeal firmly planned, Aurobindo's legal and compliance response is measured and consistent with best practice for large-cap Indian pharma companies navigating multi-year GST disputes. The GSTAT proceedings on the FOB vs CIF valuation methodology will be worth watching — a favourable ruling could extinguish the largest component of the principal demand and set a sector-wide precedent for pharmaceutical exporters facing similar IGST refund audits. For the latest Aurobindo regulatory disclosures and stock updates, follow Business Standard, The Economic Times, and Screener.in.

Disclaimer: This blog post is for informational purposes only and does not constitute investment, legal, or tax advice. All figures are sourced from regulatory disclosures filed by Aurobindo Pharma Limited. Please consult a qualified legal or tax advisor for guidance on specific GST compliance matters.